Discover the top 25 companies transforming the nuclear medicine market, including Novartis AG, Lantheus Holdings, Inc., GE Healthcare, and other industry leaders. Backed by a market projected to grow from $10.41 billion to $21.01 billion by 2030 at a CAGR of 15.1%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Nuclear Medicine Companies
Novartis AG
Novartis AG is a global leader in the development and commercialization of innovative medicines, with a significant and growing presence in the nuclear medicine market through its focus on radioligand therapy (RLT). The company’s strategic commitment to this platform is evidenced by its robust pipeline of therapeutic candidates and its state-of-the-art manufacturing facilities, such as its RLT plant in the U.S. Key assets include Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer, positioning Novartis at the forefront of precision oncology by delivering targeted radiation directly to malignant cells while minimizing impact on healthy tissue.
Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a premier radiopharmaceutical company dedicated to helping clinicians enhance patient care through innovative diagnostic and therapeutic solutions. With a history spanning over 70 years, the company offers a diversified portfolio of imaging agents, including PYLARIFY for prostate cancer and DEFINITY for echocardiography. Lantheus leverages strategic partnerships and a strong development pipeline to address unmet medical needs in oncology, cardiology, and neurology, maintaining its position as a critical infrastructure provider in the global nuclear medicine ecosystem.
GE Healthcare
GE Healthcare is a leading global medical technology and pharmaceutical diagnostics innovator, providing a comprehensive range of nuclear medicine solutions that integrate imaging equipment, radiopharmaceuticals, and digital tools. The company maintains one of the largest networks of nuclear pharmacies in the U.S. and offers advanced SPECT and PET imaging systems like the StarGuide and Discovery series. Its pharmaceutical diagnostics division produces essential tracers and contrast media, enabling healthcare providers to achieve more accurate diagnoses and tailored treatment plans across major care pathways.
Curium
Curium is the world’s largest vertically integrated radiopharmaceutical manufacturer, specializing in the production and supply of world-class radioactive tracers and therapeutic agents. Serving over 14 million patients annually across more than 60 countries, Curium focuses on enhancing the lives of people with cancer and other debilitating conditions. The company’s extensive infrastructure includes a massive distribution network and numerous cyclotrons, supporting a portfolio of over 50 products that cover critical applications in oncology, cardiology, and neurology.
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of “theranostic” (therapeutic and diagnostic) radiopharmaceuticals. The company’s flagship product, Illuccix, has established a strong commercial footprint in prostate cancer imaging. Telix is rapidly expanding its pipeline to include targeted radiation treatments for kidney, brain, and hematologic cancers, supported by a global manufacturing network and strategic collaborations with major industry players to advance the field of molecularly targeted radiation.
Siemens Healthineers
Siemens Healthineers is a global powerhouse in medical technology, offering a broad spectrum of diagnostic imaging solutions that are vital to nuclear medicine. The company’s innovative SPECT/CT and PET/CT systems provide high-resolution anatomical and functional data, facilitating early disease detection and precise therapy monitoring. Through its focus on digital health and automation, Siemens Healthineers enhances laboratory and imaging workflows, supporting the growth of precision medicine and the expanding clinical utility of radiopharmaceuticals.
China Isotope & Radiation Corporation
China Isotope & Radiation Corporation (CIRC) is a dominant player in the Chinese nuclear medicine market, specializing in the research, development, manufacture, and sale of radioisotope-branded products. The company provides a comprehensive suite of solutions, including diagnostic radiopharmaceuticals, therapeutic isotopes, and radioactive sources for industrial and medical applications. CIRC’s extensive domestic network and growing international presence make it a key contributor to the advancement of nuclear medicine infrastructure and clinical practice in the Asia-Pacific region.
Bayer AG
Bayer AG is a global life sciences enterprise with a significant presence in the nuclear medicine sector, particularly through its innovative therapeutic radiopharmaceuticals. The company’s oncology portfolio includes Xofigo, a first-in-class alpha-particle emitting radioactive therapeutic agent for the treatment of certain types of prostate cancer. Bayer continues to invest in targeted alpha therapies and strategic collaborations, aiming to provide more effective and better-tolerated treatment options for patients with advanced malignancies.
Bracco Imaging S.p.A.
Bracco Imaging S.p.A. is a world-leading provider of diagnostic imaging solutions, offering a comprehensive portfolio of contrast agents and medical devices across various modalities, including nuclear medicine. The company focuses on enhancing diagnostic accuracy and patient safety through its innovative imaging agents and injectors. Bracco’s global presence and commitment to research and development enable it to support healthcare professionals in the early detection and management of cardiovascular, oncological, and neurological diseases.
Cardinal Health
Cardinal Health is a major distributor and service provider in the healthcare industry, playing a pivotal role in the nuclear medicine market through its Nuclear & Precision Health Solutions business. The company operates an extensive network of nuclear pharmacies, providing nationwide access to patient-ready doses of diagnostic and therapeutic radiopharmaceuticals. Cardinal Health’s expertise in logistics, pharmacy management, and clinical support ensures the reliable delivery of time-sensitive radioactive materials to hospitals and clinics across the United States.
Jubilant Pharmova Limited
Jubilant Pharmova Limited, through its radiopharmaceuticals business, is a leading global provider of diagnostic and therapeutic products for the nuclear medicine industry. The company offers a diverse range of products, including cold kits for SPECT imaging and specialized therapeutic agents. With manufacturing facilities in North America and a strong distribution network, Jubilant supports healthcare providers in various clinical areas such as lung, thyroid, and bone imaging, maintaining a commitment to quality and regulatory compliance.
Eli Lilly and Company
Eli Lilly and Company has expanded its footprint in the nuclear medicine market through strategic acquisitions and a focus on radioligand therapies. By integrating advanced molecular imaging with targeted therapeutics, Lilly aims to transform the treatment landscape for oncology and neurodegenerative diseases. The company’s expertise in drug development and its growing radiopharmaceutical pipeline position it as a significant contender in the advancement of precision medicine and targeted radiation treatments.
BWXT Medical Ltd.
BWXT Medical Ltd. is a specialized provider of medical isotopes and radiopharmaceuticals, leveraging its expertise in nuclear technology to support the global healthcare industry. The company focuses on the development and manufacture of critical isotopes used in both diagnostic imaging and targeted therapies. BWXT Medical’s commitment to securing a stable supply of medical radioisotopes addresses a vital need in the market, enabling the continued growth and adoption of nuclear medicine procedures worldwide.
NTP Radioisotopes SOC Ltd.
NTP Radioisotopes SOC Ltd., a subsidiary of the South African Nuclear Energy Corporation (Necsa), is a leading global supplier of essential medical radioisotopes, including Molybdenum-99 (Mo-99) and Iodine-131 (I-131). The company operates state-of-the-art production facilities and serves customers in over 60 countries. NTP’s role as a primary producer of raw isotopes is critical to the global nuclear medicine supply chain, supporting millions of diagnostic and therapeutic procedures every year.
Eckert & Ziegler
Eckert & Ziegler is a global specialist in isotope technology for medical, scientific, and industrial use. In the nuclear medicine sector, the company provides a wide range of products, including radioactive components, radiation sources, and equipment for the production of radiopharmaceuticals. Eckert & Ziegler’s expertise in handling and processing isotopes supports the development of new diagnostic and therapeutic solutions, particularly in the growing field of targeted alpha and beta therapies.
Isotope JSC
Isotope JSC is a leading provider of isotope products and services, serving as a key link in the global supply chain for medical and industrial radioisotopes. The company facilitates the distribution of a wide array of isotopes used in nuclear medicine for imaging and therapy. Isotope JSC’s extensive logistics network and technical expertise ensure the safe and timely delivery of radioactive materials to healthcare facilities and research institutions worldwide.
PDRadiopharma Inc.
PDRadiopharma Inc. is a Japanese pharmaceutical company specializing in the development, manufacture, and sale of radiopharmaceuticals. The company provides a range of diagnostic agents used in nuclear imaging for various organs and diseases. PDRadiopharma’s focus on the Japanese market and its commitment to providing high-quality radiopharmaceutical solutions contribute to the advanced state of nuclear medicine practice and patient care in the region.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical company dedicated to developing, producing, and globally distributing innovative diagnostic and therapeutic isotopes and radiopharmaceuticals. The company focuses on targeted radionuclide therapies for cancer, utilizing its proprietary technology and extensive network of partners. ITM’s commitment to precision oncology and its robust pipeline of therapeutic candidates position it as a pioneer in the next generation of nuclear medicine treatments.
Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów – Polatom
POLATOM, the Radioisotope Centre of the National Centre for Nuclear Research in Poland, is a major manufacturer and distributor of radiopharmaceuticals and isotope-labeled compounds. The center provides a broad portfolio of products for nuclear medicine, including diagnostic kits, therapeutic solutions, and radiation sources. POLATOM’s research and production capabilities support the clinical needs of healthcare providers in Poland and internationally, contributing to the advancement of nuclear medicine technology.
ANSTO
ANSTO (Australian Nuclear Science and Technology Organisation) is Australia’s national nuclear research and development organization, and a major producer of medical radioisotopes. Through its health division, ANSTO supplies a significant portion of the isotopes used in Australian hospitals for diagnostic and therapeutic procedures. Its expertise in nuclear science and state-of-the-art facilities, including the OPAL multipurpose reactor, make it a vital player in the regional nuclear medicine ecosystem.
SHINE Technologies, LLC
SHINE Technologies, LLC is an innovative company focused on the sustainable production of medical isotopes using its proprietary fusion-based technology. The company aims to provide a reliable and domestically sourced supply of isotopes such as Molybdenum-99 and Lutetium-177, which are essential for diagnostic imaging and cancer therapy. SHINE’s commitment to developing cleaner and more efficient isotope production methods addresses critical supply chain challenges in the global nuclear medicine market.
Isotopia Molecular Imaging Ltd.
Isotopia Molecular Imaging Ltd. is an Israeli radiopharmaceutical company that specializes in the development and manufacture of innovative diagnostic and therapeutic products. The company provides a range of isotopes and radiopharmaceuticals, with a focus on targeted therapies for oncology. Isotopia’s expertise in molecular imaging and its collaborative approach with academic and industrial partners drive the development of new solutions that improve patient outcomes in nuclear medicine.
Institute of Isotopes
The Institute of Isotopes (Izotóp Intézet Kft.), based in Hungary, is a long-standing provider of radioisotope products for medical, research, and industrial applications. In the nuclear medicine sector, the company specializes in the production of radiopharmaceuticals, immunoassay kits, and radiation sources. Its extensive experience and commitment to quality make it a trusted partner for healthcare facilities and laboratories across Europe and beyond, supporting a wide range of diagnostic and therapeutic procedures.
Global Medical Solutions
Global Medical Solutions (GMS) is a leading provider of nuclear medicine and diagnostic imaging services, operating a network of radiopharmacies and imaging centers across the Asia-Pacific region and other international markets. GMS specializes in the preparation and distribution of patient-ready radiopharmaceuticals and provides comprehensive management services for nuclear medicine departments. Its focus on operational excellence and clinical quality supports the growth and accessibility of nuclear medicine services globally.
Isotex Diagnostics
Isotex Diagnostics is a specialized manufacturer of radiopharmaceuticals and diagnostic kits, providing essential tools for the nuclear medicine industry. The company focuses on the production of high-quality imaging agents used in various clinical applications, including cardiology and oncology. Isotex’s dedication to meeting the needs of clinical laboratories and imaging centers ensures a reliable supply of diagnostic products that support accurate and timely patient assessments.
Download PDF Brochure:“Click Here”
